Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials

医学 血糖性 糖化血红素 内科学 低血糖 不利影响 2型糖尿病 糖尿病 中止 随机对照试验 安慰剂 胃肠病学 2型糖尿病 内分泌学
作者
Akshaya Srikanth Bhagavathula,Kota Vidyasagar,Wubshet Tesfaye
出处
期刊:Pharmaceuticals [MDPI AG]
卷期号:14 (10): 991-991 被引量:5
标识
DOI:10.3390/ph14100991
摘要

Tirzepatide is a novel once-a-week dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, currently under trial to assess glycemic efficacy and safety in people with type 2 diabetes. A systematic review and meta-analysis were conducted to investigate the efficacy of tirzepatide on glycated hemoglobin (HbA1c, %), fasting serum glucose (mg/dL), and body weight (kg) in patients with uncontrolled type 2 diabetes (HbA1c > 7.0%). Mean changes for efficacy and proportions (safety) with corresponding 95% confidence intervals (CIs) were used to provide pooled estimates. A total of four randomized controlled trials, comprising 2783 patients of whom 69.4% (n = 1934) were treated with 5 mg (n = 646), 10 mg (n = 641), or 15 mg (n = 647) of tirzepatide, were compared to the placebo (n = 192) or the selective GLP-1 receptor agonist (n = 523). The pooled analysis showed that tirzepatide treatment resulted in a greater lowering of the HbA1c (-1.94%, 95% CI: -2.02 to -1.87), fasting serum glucose (-54.72 mg/dL, 95% CI: -62.05 to -47.39), and body weight (-8.47, 95% CI: -9.66 to -7.27). We also found that improvement in the HbA1c levels was still maintained at weeks 26 and 40 from the long-term trials. As for safety, only 3% experienced hypoglycemia, and 4% (95% CI: 2 to 6) experienced serious adverse events, while the discontinuation of therapy percentage was 7% (95% CI: 5 to 8). Tirzepatide significantly improved glycemic control and body weight and had an acceptable safety profile, indicating that it is an effective therapeutic option for glucose-lowering in patients with type 2 diabetes mellitus.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
甜叶菊发布了新的文献求助10
2秒前
2秒前
小赵同学发布了新的文献求助10
2秒前
猎人1995发布了新的文献求助10
2秒前
2秒前
希望天下0贩的0应助小赵采纳,获得10
3秒前
卡其嘛亮发布了新的文献求助10
4秒前
angki77完成签到,获得积分10
4秒前
4秒前
YUHUIFAN完成签到,获得积分10
5秒前
在水一方应助小贝采纳,获得10
6秒前
donson完成签到,获得积分10
6秒前
Starry完成签到,获得积分10
6秒前
Strike发布了新的文献求助10
6秒前
啦啦啦发布了新的文献求助10
7秒前
畅快城发布了新的文献求助10
8秒前
科小白完成签到,获得积分10
8秒前
8秒前
星渊完成签到,获得积分10
8秒前
8秒前
qiaozhi乔治发布了新的文献求助20
9秒前
研友_LmgOaZ完成签到 ,获得积分0
9秒前
Bazinga完成签到,获得积分10
10秒前
小赵同学完成签到,获得积分10
10秒前
sswbzh给刘逍遥的快乐生活的求助进行了留言
11秒前
小豆斗逗完成签到,获得积分10
11秒前
FOB完成签到,获得积分10
12秒前
一二发布了新的文献求助10
12秒前
12秒前
quanjiazhi完成签到,获得积分10
13秒前
涉川完成签到,获得积分20
13秒前
啦啦啦完成签到,获得积分10
14秒前
aaa完成签到,获得积分10
15秒前
Dr Niu应助Strike采纳,获得10
15秒前
15秒前
科研通AI2S应助韦高烽采纳,获得10
15秒前
虚幻姝发布了新的文献求助10
15秒前
TerryWei完成签到 ,获得积分10
16秒前
深情安青应助美满花生采纳,获得10
16秒前
16秒前
高分求助中
Sraffa and applied economics: are there classical supply curves? 1000
Heun’s Differential Equations 600
《Fundamentals of Power Supply Design》Robert A. Mammano 510
谁能看见前面有梦可想 500
High Wire: How China Regulates Big Tech and Governs Its Economy 260
lingnan science journal vol. 16 250
The philosophy of sports medicine care: an historical review 250
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2249459
求助须知:如何正确求助?哪些是违规求助? 1898597
关于积分的说明 4735668
捐赠科研通 1688038
什么是DOI,文献DOI怎么找? 856296
版权声明 545291
科研通“疑难数据库(出版商)”最低求助积分说明 453231